<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808912</url>
  </required_header>
  <id_info>
    <org_study_id>MU2007-028</org_study_id>
    <nct_id>NCT00808912</nct_id>
  </id_info>
  <brief_title>Does Sildenafil Increase Exercise Performance in Air Pollution?</brief_title>
  <official_title>Decreased Pulmonary Artery Pressure by Oral Sildenafil Injection During Exercise in Air Pollution Increases Exercise Performance.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marywood University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marywood University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine if the ingestion of a standard dose of sildenafil
      enhances the athletic performance of competitive athletes when exercising in a high pollutant
      environment verses a low air pollutant environment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate effects of sildenafil on exercise performance while breathing high
      levels of emission exhaust ultrafine and fine particulate matter. Exercise performance will
      be measured by work accumulation (total kJ) during a 6-min maximal effort cycle ergometer
      ride (CER) done immediately after 30 min cycling at 75% of 6 min mean watts determined from
      familiarization trial. Peak oxygen consumption, cardiac output, pulmonary artery pressure,
      diffusion capacity(DLco), and SaO2 will be determined for each trial. Blood and urine will be
      analyzed for sildenafil using LC/MS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>That a decrease in exercise performance subsequent to emissions particle inhalation will be blunted by oral ingestion of 50 mg sildenafil prior to a 6-min maximal accumulation test (total kJ)on a cycle ergometer.</measure>
    <time_frame>Cycle ergometer testing will be done one hour after administration of sildenafil or matching placebo.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>That the decreased VO2 peak and decreased exercise performance from emissions inhalation will be the result of pulmonary hypertension causing decreased stroke volume.</measure>
    <time_frame>Pulmonary artery pressure will be measured before and immediately post exercise.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>That plasma and urine sildenafil and metabolites will be measurable by liquid chromatography mass spectrometry (LC/MS) 6 h post ingestion.</measure>
    <time_frame>Blood and urine samples will be collected at 1, 3, 1nd 6 hours post exercise testing.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Pulmonary Artery Pressure</condition>
  <condition>Exercise Performance</condition>
  <condition>Air Pollution</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will exercise in a high air pollutant environment after ingesting a standard dose of sildenafil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will exercise in a low pollutant environment after ingesting a standard dose of sildenafil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will exercise in a high pollutant environment after ingesting a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will exercise in a low pollutant environment after ingesting a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>sildenafil 50 mg ingested orally 1 hour prior to exercise testing</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-asthmatic

          -  asthmatic

          -  active participants in endurance sports.

        Exclusion Criteria:

          -  history of high blood pressure

          -  history of heart disease

          -  pulmonary arterial hypertension

          -  pulmonary emboli

          -  diagnosis of moderate to severe asthma (FEV1 &lt;75% predicted)

          -  pregnant or lactating
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth W Rundell, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marywood University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marywood University</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2008</study_first_posted>
  <last_update_submitted>June 22, 2010</last_update_submitted>
  <last_update_submitted_qc>June 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kenneth W. Rundell Ph.D.</name_title>
    <organization>Marywood University</organization>
  </responsible_party>
  <keyword>phosphodiesterase</keyword>
  <keyword>sildenafil</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>exercise performance</keyword>
  <keyword>air pollution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

